Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals by Quarter
Crinetics Pharmaceuticals — Cash and cash equivalents ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals: $55.5M in Q2 2026, up 3.3% from a year earlier.
Latest, Q2 2026
55.5
Period ended Jun 30, 2026
Change on a year earlier
+3.3%
53.7 in Q2 2025
History
33 quarters
Since Q2 2018
Sources
28
Documents cited below
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Cash and cash equivalents ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 55.5 | +3.3% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | 114 | +20.9% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | 102 | -61.6% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | 111 | -65.0% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | 53.7 | -82.2% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | 94.6 | -76.1% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | 265 | +381.9% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | 317 | +122.2% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | 302 | +664.0% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | 396 | +861.2% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 54.9 | +68.0% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 143 | +362.0% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 39.6 | -36.5% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 41.2 | -71.7% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 32.7 | -83.7% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 30.9 | -80.9% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 62.3 | -65.2% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 146 | +37.9% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 201 | +115.6% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 162 | +37.1% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 179 | +11.2% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 106 | +107.3% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 93.1 | +130.8% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 118 | +77.0% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 161 | +169.3% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 50.9 | -19.0% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 40.3 | -10.3% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 66.6 | -60.8% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 59.7 | -12.7% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 62.8 | – | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 45.0 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 170 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 68.4 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals ($M), quarterly Q2 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-cash
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.